By Tony Fong

NEW YORK (GenomeWeb News) – With two recent deals, Life Technologies is positioning itself to capitalize on what could be the next big market opportunity in the life sciences.

During the past two weeks the Carlsbad, Calif.-based company has completed two deals giving it a seat at the synthetic biology table — a field with a market size that has been projected to reach $2.4 billion by 2013.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.